Architectural Nexus’ Post

NEWS: Construction Underway for Michigan State University + Henry Ford Health Biomedical Research Center -- Michigan State University (MSU) and Henry Ford Health have joined forces to construct the $335 million Henry Ford Health + Michigan State University Research Center, which will house 84 principal investigators and their research teams focused on cancer, neuroscience, infectious diseases, immunology, and public health. The first floor will accommodate a large core lab including an imaging suite. An entire floor will be dedicated to the Nick Gilbert Neurofibromatosis Research Institute. At 335,000 sf and seven stories, it will be will be MSU’s largest research facility. As part of a 30-year partnership begun in 2021, the center will be owned by MSU on land leased from Henry Ford Health, and operated jointly by both institutions. The venture is part of a $3 billion development group that includes the Detroit Pistons basketball organization. The “Future of Health” project will feature a new hospital tower and 600 units of mixed-income housing. Designed by ZGF Architects with Barton Malow as the construction manager, the facility is expected to open in 2027. https://lnkd.in/eRX6QcSU #Collaboration #GroundBreaking #InterdisciplinaryResearch #Biomedical #Healthcare #HigherEducation #ResearchandDevelopment

Looking forward to results of these studies

Using AI and functional connectivity on scalp EEG to delineate the epileptogebic zone. Our new paper is out on Epilepsia, #ILAE ! Congratulations to the whole team at Boston Children's Hospital Neurology, #FNNDSC and especially to Eleonora Tamilia and to Navaneethakrishna Makaram! #epilepsy #medicalresearch #childneurology #ndd #residency #FNNDSC #artificialintelligence #epilepsia #ilae https://lnkd.in/ebFm-HJ4

🌟 Spotlight on Dr. Greer Waldrop! 🌟 We're excited to highlight Dr. Greer Waldrop from The University of California, San Francisco, one of the recipients of the FSR Sarcoidosis Research Fellowship Grant. Her project, titled "Defining Neurosarcoidosis: From Disease Activity to the CNS Transcriptome," is set to revolutionize our understanding of neurosarcoidosis. Dr. Waldrop's research aims to fill crucial gaps in the field by creating a standardized framework for classifying disease activity and conducting the first-ever transcriptomic analysis from the central nervous system. This groundbreaking work will enhance our understanding of neurosarcoidosis and pave the way for better diagnostic and therapeutic strategies. Join us in celebrating Dr. Waldrop's dedication to advancing sarcoidosis research and the significant impact her work will have on patients' lives. 🎉 #Neurosarcoidosis #SarcoidosisResearch #FSRFellowship #InnovativeResearch #StopSarcoidosis

Nice! From Naveen Rao’s coverage of neurotech at #jpm2024: “What Is Neurotech’s ‘Killer App’? For JPM’s biotech attendees, a neurotechnology home run would be a reliable diagnostic test (like a set of biomarkers) for earlier detection of mild cognitive impairment and/or Alzheimer's disease.” https://lnkd.in/giHxqNZM At Kernel, we’re applying our one-of-a-kind neurotechnology (Kernel Flow) and working with our clinical research partners to build an early detection biomarker for MCI…. And seeing promising results! https://lnkd.in/gviSWniN

🧠 Poietis Partners in the Groundbreaking 4-DBR Project 🧠 We are proud to be partner in the 4-Deep Brain Reconstruction (4-DBR) initiative, a Horizon European Innovation Council (EIC) Pathfinder Open project aimed at revolutionizing the treatment of neurodegenerative disorders. 🔗https://www.4dbr.eu/ The 4-DBR project is a collaborative effort to develop a conceptually novel approach for brain reconstruction, seeking to provide a groundbreaking solution for patients suffering from conditions that currently have limited treatment options. 🎥 As part of this collaboration, we're excited to share the project's launch video, offering a window into the innovative strategies we're exploring together. 📅 This coming Thursday marks an important milestone as we head into the annual consortium meeting for the 4-DBR project. Fabien Guillemot and Deepshika Arasu from Poietis, will participate and contribute to the discussions that will shape the future of this ambitious project. #4DBR #Poietis #NeurodegenerativeDiseases #HorizonEurope #Bioprinting #HealthcareInnovation #ScienceandTechnology #ConsortiumMeeting

Project Spotlight: PREBO-6 Dive into the pioneering research happening at Herston Imaging Research Facility with Child Health Research Centre The University of Queensland for PREBO-6! Our team is at the forefront of predicting childhood brain outcomes in preterm infants using neonatal MRI and clinical biomarkers. By combining advanced imaging techniques with clinical assessments, we're aiming to identify infants at risk of adverse neurodevelopmental outcomes early on. This study, focusing on a cohort of very preterm infants at 6 years CA, holds immense promise in informing prognosis and guiding interventions. Plus, our cutting-edge MRI imaging techniques, including motion-correcting WIP ABCD C2P sequences, ensure high-quality data even in non-compliant patients like children. #PREBO6 #ChildhoodBrainOutcomes #NeonatalMRI #ResearchInnovation

Yes, you’re correct. Neurosurgeon Craig van Horne is indeed pioneering a new approach to potentially slow or reverse the progression of Parkinson’s disease. This approach, known as DBS+ (Deep Brain Stimulation Plus), combines the established treatment for advanced Parkinson’s, which is an electrode-implanting surgery known as Deep Brain Stimulation (DBS), with an experimental nerve-grafting procedure. In DBS+, the surgeon transplants peripheral nerve tissue into an area of the brain where neurons are dying. The grafted cells are being tested for their ability to release chemicals believed to rejuvenate the brain’s weary dopamine-producing neurons1. Peripheral nerves, which lie outside the brain and spinal cord, have regenerative qualities that nerves inside the brain do not. The UK team hopes to leverage those regenerative effects within the brain, potentially halting or reversing nerve damage caused by Parkinson’s. The DBS+ procedure has been performed in 60 patients, with initial results of the Phase 1 study being highly encouraging. Early participants have shown a clinically important improvement in symptoms, marked by a decrease in scores on the UPDRS (Unified Parkinson’s Disease Rating Scale) – the most widely used clinical rating scale for Parkinson’s. #consultantemerfalen #consultancyemerfalen

If you are interested in the role of IFN type I signalling in the brain, like me, then this recent publication will interest you. 🧠 Ethan R. Roy et al. just plublished their article ‘Fate-mapping and functional dissection reveal perilous influence of type I interferon signaling in mouse brain aging’. Very interesting read! 🔬 https://lnkd.in/d6csvhtH

Check out the link below to review the latest edition of "Brain Waves" highlighting the most recent news and accomplishments from Le Bonheur's Neuroscience Institute. In this issue, you'll read about Sophia Cope -- a child who is part of the first and only clinical trial in the world for SCN2A treatment held at Le Bonheur. Plus, we recently treated the first patient in Tennessee with ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy. You'll also learn about our latest symposium that brought together pediatric neurosurgeons from around the world to discuss the surgical nuances of neurosurgery for nervous system tumors in children. https://ow.ly/upeU50QgV5g